(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Selective antagonist of vasopressin V1A receptor that inhibits vasopressin and oxytocin-induced increases in intracellular calcium concentrations in vitro (IC50 values are 5 and 30 nM respectively). Exhibits potent and prolonged antivasopressor activity and induces anxiolytic-like effects in the dorsal, but not ventral, hippocampus in vivo.

Online Inquiry

Specification Technical Data Related Products Customer reviews and Q&A Useful Tools Publications

CAT#	R1081
CAS	73168-24-8
Synonyms/Alias	Manning Compound, [Pmp1, Tyr(OMe)2, Arg8] Vasopressin; β-Mercapto-β,β-cyclopentamethylene-propionyl-Tyr(Me)-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 trifluoroacetate salt (Disulfide bond)
M.F/Formula	C52H74N14O12S2
M.W/Mr.	1151.38
Sequence	YFQNCPRG(Modifications: Tyr-1 = Pmp-Tyr(Me), Gly-8 = C-terminal amide)
Labeling Target	Vasopressin Receptor
Appearance	White lyophilised solid
Purity	>98%
Activity	Antagonist

CAT#	Product Name	Inquiry
R1573	NY-BR-1 p904 A2	Inquiry
R1476	Laminin 925-933	Inquiry
R1860	CGRP (8-37), human	Inquiry
HB00038	Biotin-LLY-FMK	Inquiry
HB00023	Biotin-FF-FMK	Inquiry

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Source#	Synthetic
Storage	-20°C
InChI	InChI=1S/C52H74N14O12S2/c1-78-32-16-14-31(15-17-32)25-35-46(73)63-36(24-30-10-4-2-5-11-30)47(74)61-34(18-19-40(53)67)45(72)64-37(26-41(54)68)48(75)65-38(29-79-80-52(27-43(70)60-35)20-6-3-7-21-52)50(77)66-23-9-13-39(66)49(76)62-33(12-8-22-58-51(56)57)44(71)59-28-42(55)69/h2,4-5,10-11,14-17,33-39H,3,6-9,12-13,18-29H2,1H3,(H2,53,67)(H2,54,68)(H2,55,69)(H,59,71)(H,60,70)(H,61,74)(H,62,76)(H,63,73)(H,64,72)(H,65,75)(H4,56,57,58)/t33-,34-,35-,36-,37-,38-,39-/m0/s1
InChI Key	QVQOGNOOAMQKCE-ZTYVOHGWSA-N
Isomeric SMILES	COC1=CC=C(C=C1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC3(CCCCC3)CC(=O)N2)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N)CC5=CC=CC=C5
BoilingPoint	N/A
Melting Point	N/A